Boardroom Alpha
Boardroom Alpha
TDAC · Additional Proxy Materials (DEFA14A) · Filed June 23, 2026

Translational Development Acquisition Corp — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
June 23, 2026
Ticker
TDAC
Accession
0001104659-26-076687
Boardroom Alpha · Filing insights

Translational Development Acquisition Corp. reports shareholder redemptions and extension vote results, and outlines its ProLogium merger.

About Translational Development Acquisition Corp
Market cap
$209M
1Y TSR
+5.0%
Sector
Industrials
CEO
Michael B Hoffman

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 22, 2026

 

TRANSLATIONAL DEVELOPMENT ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

 

Cayman Islands   001-42451   N/A
(State or other jurisdiction of
incorporation or organization)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

52 E. 83rd Street,

New York, New York

  10028
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (917) 979-3072

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading
Symbol(s)
Name of each exchange
on which registered
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant TDACU The Nasdaq Stock Market LLC
Class A ordinary shares, $0.0001 par value per share TDAC The Nasdaq Stock Market LLC
Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 TDACW The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01 Other Events.

 

On June 22, 2026, Translational Development Acquisition Corp. (the “Company” or “TDAC”) issued a press release announcing certain results of shareholder redemptions in connection with the shareholder vote held on June 17, 2026 regarding the extension of the deadline by which TDAC must consummate an initial business combination and providing certain information regarding TDAC’s proposed business combination with ProLogium Holding Inc. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

The information contained in this Current Report on Form 8-K, including Exhibit 99.1, is being filed for purposes of Rule 425 under the Securities Act of 1933, as amended, and Rule 14a-12 under the Securities Exchange Act of 1934, as amended.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are being filed herewith:

 

Exhibit No. Description of Exhibits
99.1 Press Release, dated June 22, 2026.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 23, 2026 TRANSLATIONAL DEVELOPMENT ACQUISITION CORP.
     
  By: /s/ Michael B. Hoffman
  Name: Michael B. Hoffman
  Title: Chief Executive Officer

 

 

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Translational Development Acquisition Corp (TDAC)

Reference

Frequently asked questions

When did Translational Development Acquisition Corp file this DEFA14A?
Translational Development Acquisition Corp (TDAC) filed this Additional Proxy Materials (DEFA14A) with the SEC on June 23, 2026. The accession number assigned by EDGAR is 0001104659-26-076687.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Translational Development Acquisition Corp. reports shareholder redemptions and extension vote results, and outlines its ProLogium merger. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Translational Development Acquisition Corp's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Translational Development Acquisition Corp has filed under CIK 1926599, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer